The FDA’s approval is a victory for GSK in a race against Pfizer and Moderna to bring a shot that targets respiratory syncytial virus to the market.
More Stories
Boeing machinists on picket lines prepare for lengthy strike: ‘I can last as long as it takes’
More than 30,000 Boeing machinists walked off the job Sept. 13. At a local union office outside Seattle, they prepared...
Ethereum Foundation sells 300 ETH as price hits $2.5k
The Ethereum Foundation has sold a total of 950 ETH worth over $2.2 million in the past three weeks On...
Boeing’s defense unit chief Colbert is departing, CEO says
CEO Kelly Ortberg said a replacement for Ted Colbert would be named later.
FTC sues drug middlemen for allegedly inflating insulin prices
The FTC suit targets the three biggest so-called pharmacy benefit managers, UnitedHealth Group's Optum Rx, CVS Health's Caremark and Cigna's...
Family offices are the most bullish they’ve been in years, survey says
Nearly half of family offices are expecting double-digit returns this year, according to Citi Private Bank's 2024 Global Family Office...
The Biggest Concern After Fed Rate Cuts Is Not What You Think
At long last, after four years, the Federal Reserve has finally cut the Fed Funds rate by 50 basis points,...